Ticker

No recent analyst price targets found for MRNY.

Latest News for MRNY

MRNY: Strong Income Run Masks Rising Downside Risk

YieldMax MRNA Option Income Strategy ETF (MRNY) is maintained as a Sell due to heightened downside risk and overvalued pipeline optimism. MRNY's aggressive 100% covered call strategy captures some upside but offers limited downside protection and lower income in flat markets. Moderna's (MRNA) revenue base is structurally declining, with oncology pipeline progress already priced into an elevated EV/revenue multiple.

Seeking Alpha • Apr 8, 2026
3 ETFs Catapulting Beyond the S&P to Start the Year

About a month into the new year, exchange-traded funds (ETFs) are beginning to build up enough of a performance record for 2026 to potentially differentiate themselves from the broader market. The funds with the best track record in 2026 may surprise some investors.

MarketBeat • Jan 29, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for MRNY.

No Senate trades found for MRNY.

No House trades found for MRNY.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top